Get started

2019

NRXP COVID-19 Vaccine Effectiveness Against Delta VariantNRx Pharmaceuticals announced that its BriLife COVID-19 Vaccine is Effectiveness Against Delta Variant. Information was released by Israel Institute for Biological Research. Since the pandemic isn`t over, there is a place in the market for new developers that have effective vaccines. I consider this a premium call, the upside i see here is 400%, or the 24usd resistance. NRXP 52 Week Range 4.07 - 76.99usd. Now the price is 6.75usd. Is this a buy or not? Market Cap of only 396.97Mil
NASDAQ:NRXPLong
by TopgOptions
1
Merck Stocks Have a 25% Growth PotentialToday we will review Merck & Co stocks as I have promised recently. The company announced the launch of the first oral medication against COVID-19 with proven efficiency. Let’s analyse the chart with the Merck stocks and their upside potential. When doing analysis it is traditionally better to start from the eldest timeframes to distinguish the existing trend. So, if we look at the monthly timeframe chart of Merck stocks we may find an upward trend that started in March 2009. We may also see a consolidation since January 2020 that lasted until September 2021, that is forming a triangle. This figure acts as a continuation sequence of the trend as the upward breakthrough has already been made. The breakthrough occurred on October 1, when the company announced successful clinical trial results of its anti-COVID-19 pill. This announcement was made a week before and no other news has been announced concerning this. This triangle provides a potential for Merck stocks to go to the $103.50-104 area. So, it is a potential gain of 25-26% from the current price. Moreover, the gap on October 1 is now acting as a key support level. Nevertheless, technically we may have a retest of the upper triangle margin at the $78.50-$79.30 area. But even if this retest does not happen, as it is not always the case, it is worth to consider adding these stocks to the portfolio. It should be noted that this technical pattern has been forming for several months and we should expect that the upside scenario would be effective for a while still. It may take 2-3 month, or even more, to reach the mentioned targets. However, such long-term technical patterns usually provide a good profit for those who are not looking for a checkered fortune.Merck has made contracts to deliver its pills not only in the United States, but also with other governments that are currently considering purchasing this new medication.
NYSE:MRKLong
by scavoanastasiia
LYV Long. Covid news related positive sectors breakoutLive Nation Entertainment Live Nation Entertainment, Inc. is an entertainment company, which engages in producing, marketing and selling live concerts for artists via global concert pipe. It operates through the following segments: Concerts, Sponsorship & Advertising and Ticketing. The Concerts segment involves in the promotion of live music events in owned or operated and in rented third-party venues. The Sponsorship and Advertising segment offers sales force that creates and maintains relationships with sponsors through a combination of international, national, and local opportunities that allow businesses to reach customers through concerts, venue, festivals and ticketing assets, including advertising on websites. The Ticketing segment includes selling of tickets for events on behalf of clients and retains a fee, or service charge for these services. The company was founded in 1996 and is headquartered in Beverly Hills, CA. Average Analyst Price Target : $101 : Moderate Buy Hedge Fund Trend: ▼ Hedge Funds Decreased Holdings by 6.2M Shares Last Quarter News Sentiment : Neutral Technicals : Positive With the news of the pills from Merck showing signs of low hospitalization cases and deaths in the trials, most of the sectors/stocks that were beaten down with economy slowdown/closures like casinos. gamings, airlines and cruise liners saw a surge of investor interest. Most stocks in these sectors tested and broke through important resistance zones. With sector rotation that seems to happening in the broader indices, these sectors may well see a rally for sometime and news related moves are expected. Overall price action on both Daily and Weekly candles looks great and back with the bulls. I would like to buy the dips and long stock as long as price remains outside the band on Daily candle close basis.
NYSE:LYVLong
by LoveForCharts
SINGAPORE COVID-19 Wave 3 Projection Update X (Part 1)Based on the Weekly chart... There was NO end to the wave, a slight reprieve, but it was there, clear and present. Sine the week of 19 July, it was a crossover, one that is significant and not to ignore. On the week of 30 August, the uptick was telling that the trend is real and resuming. Now SG would really feel it now as the rate is clearly accelerating over the last two weeks. Projections in line with the SG MOH press statement. We dropped the ball. Period.
C
by Auguraltrader
Is BTC's uptrend following COVID's?First off, this is not meant as any opinion towards Covid-19 (political, medical, or otherwise) nor meant in any way to dishonor any who have lost loved ones due to Covid-19, but rather I wanted to call out an interesting correlation that looks to be occurring. Recently TradingView made the confirmed cases in the US available broken down per state or country. However, when one maps the rate of change ( ROC ) based on the absolute value, one can see the daily increase/decrease in cases over time (similar to all the charts as shown on other sites such as Google ). What is interesting is that when vaccines hit key events, the price of bitcoin dropped. However, now that the delta variant has begun to increase the case rates in the US, the price of bitcoin seems to be retracing upward along almost the exact same Fibonacci retracement levels (note how even the bounces seem to occur on both charts along the Fibonacci lines). As to the cause of this, it could be for any number of reasons, for example Fibonacci levels being a measure of growth (and hence very appropriate for disease spreads), or could be correlated to the hopes for a government stimulus in the United States, or could simply be an interesting coincidence and nothing else. It seems like something of interest to watch to see if the trend continues or breaks (e.g., could a dip in Covid-19 cases due to boosters or herd immunity leading to a dip in BTC ). Either way, stay safe out there, both with the pandemic and with your trades. And as always, this is not meant as financial advice but is solely my opinion, but please like or comment if you agree or at least find it interesting as well.
C
by crypto_trends
3
BTC 2019 cycle pattern repeating!The current market is looking very much like the 2019 Market just before the covid sell off began in both the chart and the RSI. If we can not hold the 21 weekly MA as support, I believe a visit back to 30k is looking very likely before the next major run up to and above 100k. Without the Heavy Covid FUD of 2019, this potential sell off may not be so severe. This is why I dont think we will dip below 30k, but anything is possible. Thoughts and feedback please.
BITFINEX:BTCUSDShort
by louisville51
3
Ok. Pfizer is going NUTS! 🚀🚀🚀Nothing is more profitable than fear. I think Pfizer profits have doubled by Q2 and it's getting even crazier, way crazier. The whole west is throwing money at them with government and most urbanites in total fear. They don't even care how much it costs. Destroy a country? Lose 10% of GDP? They don't care, just name your price. Take AMZN for example. Went vertical, retested ATH, then to the moon. In the short term (2-3 months or even less) it can be really profitable. Who cares if Pfizer gets destroyed by crowds after we made our money? It won't happen overnight (probably). Here it's different from Amazon there is no reason for the company to trend for years (for now). It's really short term with the hysterical fear pushing profits to incredible levels. Share prices have a tendency to retrace after breaking ATH, once again, profitable in the short term. I'm not stock trader but here it is really juicy. I'm sure there are similar examples? Price just going vertical... 1999 bubble for sure... I am not experienced enough but I assume it always or almost always retests ATH I'm sure it's possible Pfizer just goes vertical, the noob bagholding investors as always will want to greedily snatch their profits the moment they see some green and cause a pullback but euphoria could absorb the selling. Something like that.... Consolidation... And again... Got to check my favorite example Moderna for 2 years has simply been in a beautiful trend, a work of art. And it is up more than 1000% since 2020. Some to compare moderna to: Other cool trends
NYSE:PFELong
by MrRenev
4
BIOV -- FDA approval for COVID-19 clinical trialsBiotech sector is getting hot, especially for companies connected to COVID-19 vaccine and treatments development... BIOV chart looks rip for a breakout with MACD closing in on bullish cross and a major catalyst in the form of FDA approval of its Phase I/II study: FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has provided its official Written Response to the Company's request for a Pre-IND Type B review of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2. The FDA found the Chemistry, Manufacturing and Controls, and other elements of the clinical development program proposed by BioVaxys to be acceptable and provided guidance and feedback supportive of BioVaxys' clinical development plans for CoviDTH. In addition, the FDA indicated that animal toxicity studies for CoviDTH were not required and that the Company could start its clinical development program with a combined Phase I/II study. Based on this feedback, BioVaxys will begin preparation of an IND application to support a Phase I/II safety, dosing, and efficacy study. BioVaxys submitted a Pre-Investigational New Drug ("IND") meeting request and briefing package with the FDA's Center for Biologics Evaluation and Research (CBER) for CoviDTH earlier this year. The Pre-IND review is a critical step in the US regulatory approval process, as it affords an opportunity for study sponsor companies to seek clarification from the FDA on clinical trials design, clinical materials manufacturing, quality controls, etc. "With the guidance we received from this FDA review, BioVaxys is now able to begin preparing its IND," stated BioVaxys President and Chief Operating Officer Ken Kovan. He adds "Although the FDA has indicated that our planned animal tox study is discretionary, we will likely continue with the animal tox study of CoviDTH as it does not interfere with the development time frame and may in fact provide useful data." James Passin, BioVaxys CEO, stated, "We are pleased to advance CoviDTH towards clinical trials, as we believe that mass screening for T cell immunity to Covid-19 will represent a critical tool for public health authorities to address the continued pandemic, as Covid variants continue to circulate and major governments in the southern hemisphere enact new lockdown policies." The Company is not making any express or implied claims that its product has the ability to eliminate, cure, or contain Covid-19 (SARS-CoV-2) at this time.
CSE:BIOVLong
by wealth_bakery
NRBO 400% Upside Potential | Covid-19 TreatmentOn 4/20/2021 HC Wainwright brokerage Reiterated Rating to Buy and a Price Target of $16.00 for NRBO But how come? What`s the catalyst? Why NeuroBo Pharmaceuticals was up 40% yesterday? Richard J. Kang, CEO: "Throughout the first quarter of 2021, we continued to make progress advancing the 60-patient Phase 2/3 clinical trial of our lead drug candidate, ANA001, a proprietary oral niclosamide formulation, as a treatment for moderate to severe COVID-19." "we expect to report preclinical in vitro data demonstrating Gemcabene's ability to treat COVID-19 variants alone and in combination with ANA001." "NeuroBo has the financial foundation to fund operations at the current level into the fourth quarter of 2021 and we expect to achieve a number of value-creating milestones with our COVID-19 programs in the coming months." Besides the Covid-19 treatment, NeuroBo Pharmaceuticals has a current portfolio of four drug candidates focused on developing and commercializing multi-modal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. The Market Cap if only 88.473Mil at the time or writing!
NASDAQ:NRBOLong
by TopgOptions
4
Carnival Corporation and plc (CCL) for long termSignals Position: long Entry price: 18.5 Target price: 28 Stop loss: 19 Indicators RSI is very low under 25, better to wait till the price reaches the support line around 18. Bullinger Bands and William Alligator are really opened, indicating a strong trend. So the price will probably reach the support. ADX is really strong, indicating a strong momentum. It means that the price will lower again. Same clues from the MACD . Conclusions Carnival is expecting to have 42 ships back to service by the end of November, embracing a phase of operations restart. After the drop caused by the Covid-19, the company is sailing again in several destinations including the Caribbean, the Mediterranean and Northern Europe. As the vaccine campaign goes on, older people ( the major costumers of the cruise industry) will be fully protected and will buy tickets. In the long term the price can reach $40 but if you want to be more conservative set the target price around 28/30.
NYSE:CCLLong
by vf_investment
GBPUSD confirms bearish flag on UK “Freedom Day”Looming concerns over the Delta covid variant probes the UK’s total unlock on July 19 as the infections jump to the highest since January. The same drag the GBPUSD prices to break the monthly rising channel, confirming the bearish flag chart pattern in turn. Given the MACD conditions also supporting the sellers and the RSI line having a bit gap from the oversold area, the quote is likely to extend the south-run towards the 1.3700 threshold and then to April’s low near 1.3670. However, any further downside will not hesitate to refresh the yearly low, currently around 1.3450. Meanwhile, corrective pullback beyond the channel’s support line, now resistance around 1.3780 will aim for the 1.3800 round figure. Though, a downward sloping trend line from June 23, near 1.3875, will be a tough nut to crack for the GBPUSD bulls afterward. Even if the cable buyers manage to cross the 1.3875 hurdle, the stated channel’s resistance line and 200-SMA, respectively around 1.3925 and 1.3945 will challenge the pair’s further upside.
Short
by MTradingGlobal
Biotech - CSLModel has given entry signals for CSL Limited: - CSL Limited is a global specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. - We are very excited about opportunities in the biotech sector, as we believe the fight against COVID is going to move to the next phase in the nearest future. - Technically in a Wyckoff accumulation structure with a spring, possibly testing the channel top. GLHF, DPT Disclaimer: We absolutely do not provide financial advice in any shape or form. We do not recommend investing based on our opinions and strongly cautions that securities trading and investment involves high risk and that you can lose a lot of money. Loss of principal is possible. We do not recommend risking money you cannot afford to lose. We do not guarantee future performance nor accuracy in historical analyses. We are not registered investment advisors. Our ideas, opinions and statements are not a substitute for professional investment advice. We provide ideas containing impersonal market observations and our opinions. Our speculations may be used in preparation to form your own ideas.
ASX:CSLLong
by UnknownUnicorn1043646
ASX:CATHere we have the lifetime chart for ASX:CAT. - Starting with a price of $0.63 and reaching an ATH of $4.26 in only 1 year. - It then went on a 3 year downtrend back to its original $0.63. - After that we see it recover to $2.13 in 1 year. - COVID-19 pandemic brings price all the way down to $0.49, which is its new ATL. - Since then price has recovered nicely, and if it continues to do so I will be looking to enter a trade. I have marked what I would like to happen for me to enter, and the relevant buy zone. I will only be putting a small sum on this trade in the hopes that price breaks the $2.47 resistance line and holds price. Only then will I be looking at this trade more seriously. I can then average down my purchase price with small sum previously purchased. DYOR I hope this helps someone
ASX:CATLong
by jakebabula
UK COVID-19 Next Wave Projection Update IIFrom the previous post on 14 May, I was doing a friend a favour into looking at the UK projection as she is living in London. I said "... and projection made that the start of a spike is at the end of June, into July . IF this projection is on point, then outnbreak news should be seen in the latter part of July ." It is the beginning of July, and it appears that the AMCD histograms trended up as expected, and is about to break out into a major spike given the weekly chart is about to crossover into the bullish territory. The daily chart is clearly showing the spike in force... go see it. So there you have it, yet again, this MACD model is projecting very well the onset of spikes. IF the powers that be, could appreciate this heuristical statistics, we might be able to intervene appropriately. In any case... the weekly MACD is about to cross up, which is seriously bad news!
C
by Auguraltrader
INDONESIA COVID-19 - the next wave part IVPreviously projected to explode in mid-June, with clear media coverage about the next wave. Today, the last day of June, in the media - I ndonesia's COVID-19 situation nears 'catastrophe', says Red Cross The model here is good at projecting with at least a 4 weeks lead time for potential waves. This was previously demonstrated for a couple of countries and all have not yet disappointed. Often, the onset is actually faster than projected... mostly attributed to the increasing virulence of the virus. Difficult to disagree with Red Cross... it IS heading that way. Prayers and well wishes to those in Indonesia, especially my friends living there. Stay safe and well. Take good care.
C
by Auguraltrader
KNR -- Oversold; Double Bottom at .89. On watch for a bounce.KNR has been beaten down but looks way overdone, given they have just raised $8.5 at 1.50 with institutional investors. The company reported respectable $3.3M revenues in Q1 2021. Their BioCloud COVID-19 detection device will be used by the Canadian Olympic delegation at the Tokyo Olympics. The US sales channel is being worked on. Insiders are buying in the open market. Share buyback program is in effect. Bullish MACD divergence on the chart.
NEO:KNRLong
by wealth_bakery
1
INDONESIA COVID-19 - the next wave part IIIJust barely a week after the last update, the rate of spread (and detection) has hit 20,000 per day ! And according to the Weekly chart (not shown here), the MACD Histograms cross over this week! This means that there is a lot more momentum for this wave to grow. Much more so given the lack of effective measures implemented and enforced. A overwhelming shutdown of the health system is pretty much round the corner, without infection rates slowing, but accelerating on the contrary. Eventually, it will affect the region, as the viral reservoir gets dug in deep, and may even see the spawn of more variants. It is expected that the rate will only increase, until very strong measures are taken to impede the spread. Until then, it would still take weeks after implementation to subside significantly. Hong Kong has already banned flights, and more will probably follow, leading to some level of external isolation. Not good at all... Take care, take very good care if you are in the affected areas. God speed, and God bless.
C
by Auguraltrader